At the time of writing, IO Biotech Inc [IOBT] stock is trading at $0.58, up 5.18%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The IOBT shares have gain 20.55% over the last week, with a monthly amount drifted -72.08%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
IO Biotech Inc [NASDAQ: IOBT] stock has seen the most recent analyst activity on September 30, 2025, when TD Cowen downgraded its rating to a Hold. Previously, Morgan Stanley downgraded its rating to Equal-Weight on September 30, 2025, and kept the price target unchanged to $0.39.
For the past year, the stock price of IO Biotech Inc fluctuated between $0.32 and $2.79. IO Biotech Inc [NASDAQ: IOBT] shares were valued at $0.58 at the most recent close of the market.
Analyzing the IOBT fundamentals
Gross Profit Margin for this corporation currently stands at -0.28% with Operating Profit Margin at -116.71%, Pretax Profit Margin comes in at -121.26%, and Net Profit Margin reading is -122.34%. To continue investigating profitability, this company’s Return on Assets is posted at -2.46, Equity is -2.82 and Total Capital is -4.42. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 5.25.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that IO Biotech Inc [NASDAQ:IOBT] has a current ratio of 1.96. Further, the Quick Ratio stands at 1.96, while the Cash Ratio is 1.41.
Transactions by insiders
Recent insider trading involved Hunter Heidi, Director, that happened on May 30 ’25 when 15000.0 shares were purchased. Chief Medical Officer, Ahmad Qasim Iftikhar completed a deal on Dec 23 ’24 to buy 31350.0 shares. Meanwhile, Chief Executive Officer Zocca Mai-Britt bought 12500.0 shares on Dec 23 ’24.
